Health news
The Food and Drug Administration (FDA) has expanded the approval of Dupixent® (dupilumab) to include add-on maintenance treatment of patients 6 to 11 years of age with moderate to severe asthma characterized by an eosinophilic…
Topline results were announced from two phase 3 studies evaluating a fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in patients with asthma. The multicenter, randomized, double-blind, parallel-group MANDALA…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021